



May 8 2026

AFT Pharmaceuticals to announce full year results on Thursday May 21 2026

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) announced today that it intends to release its full year FY2026, ended March 31 2026, results on Thursday May 21 2026. The release will be issued at around 09:00 am (NZT) on the NZX and ASX.

Following the release, management will present via webinar at 10:30 am (NZT). Presentation material will be available on the company's website [AFT](#), the NZX website [NZX](#) and the ASX website [ASX](#).

To participate in the upcoming earnings webinar, please pre-register with the link provided below. Webinar details will be provided upon completion of your registration.

Registration Link: [AFT results presentation FY2026](#)

For and on behalf of AFT Pharmaceuticals Limited, Malcolm Tubby, CFO.

For more information:

Investors

Malcolm Tubby
CFO, AFT Pharmaceuticals Ltd
Phone: +64 9 488 0232
Email: malcolm.tubby@aftpharm.com

Media

Richard Inder
The Project
Phone: 021 645 643
Email: richard@theproject.co.nz

AFT is a growing New Zealand based multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs¹. Our business model is to develop and in-license products for in our markets of Australia, New Zealand, Singapore, Malaysia, Hong Kong, USA, Canada, EU ex Ireland and UK, and to out-license our products to local licensees and distributors to over 125 countries around the world.

For more information about the company, visit our website www.aftpharm.com.
